Literature DB >> 20154713

Protective action of tetramethylpyrazine phosphate against dilated cardiomyopathy in cTnT(R141W) transgenic mice.

Hai-ping Zhao1, Dan Lü, Wei Zhang, Li Zhang, Shu-mei Wang, Chun-mei Ma, Chuan Qin, Lian-feng Zhang.   

Abstract

AIM: Dilated cardiomyopathy (DCM) is the most common cause of heart failure, and pharmacological intervention is not currently available. Here we investigate the effect of tetramethylpyrazine phosphate (TMPP) on the progression of DCM in the cTnT(R141W) transgenic mouse model.
METHODS: The cTnT(R141W) transgenic mice aged 2 months were divided into model group and TMPP group, whereas age-matched nontransgenic mice were used as wild-type control. TMPP 45 mg.kg(-1).d(-1) was administered for 7 months. Following assessment of cardiac function by echocardiography, cardiac tissues were prepared for histology and electron microscopy. Levels of molecular markers for cardiomyocyte hypertrophy and fibrosis were detected by RT-PCR. Expression of structural proteins of the sarcomere and intercalated disc was determined by Western blot.
RESULTS: TMPP significantly prevented cardiac dilatation and dysfunction with the development of DCM, and decreased mortality by 54%. TMPP decreased HW/BW ratios and expression of hypertrophic markers BNP and ACTA1, as well as reduced interstitial collagen deposition and expression of profibrotic markers Col1a1 and Col3a1. TMPP attenuated ultrastructural disruption caused by cTnT(R141W) expression and decreased expression of structural proteins myotilin and E-cadherin which were up-regulated in the cTnT(R141W) heart. Moreover, TMPP reduced the mRNA expression of Calm1 and Camk2b in the cTnT(R141W) heart.
CONCLUSION: Our results suggest that TMPP could be a promising drug for prevention and treatment of DCM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154713      PMCID: PMC4002419          DOI: 10.1038/aps.2010.6

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  34 in total

1.  Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy.

Authors:  M Kamisago; S D Sharma; S R DePalma; S Solomon; P Sharma; B McDonough; L Smoot; M P Mullen; P K Woolf; E D Wigle; J G Seidman; C E Seidman
Journal:  N Engl J Med       Date:  2000-12-07       Impact factor: 91.245

2.  Novel cardiac troponin T mutation as a cause of familial dilated cardiomyopathy.

Authors:  D Li; G Z Czernuszewicz; O Gonzalez; T Tapscott; A Karibe; J B Durand; R Brugada; R Hill; J M Gregoritch; J L Anderson; M Quiñones; L L Bachinski; R Roberts
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

3.  myotilin Mutation found in second pedigree with LGMD1A.

Authors:  Michael A Hauser; Cecilia B Conde; Valeria Kowaljow; Guillermo Zeppa; Ana L Taratuto; Udana M Torian; Jeffery Vance; Margaret A Pericak-Vance; Marcy C Speer; Alberto L Rosa
Journal:  Am J Hum Genet       Date:  2002-11-11       Impact factor: 11.025

4.  The antiplatelet activity of tetramethylpyrazine is mediated through activation of NO synthase.

Authors:  J R Sheu; Y C Kan; W C Hung; C H Lin; M H Yen
Journal:  Life Sci       Date:  2000-07-14       Impact factor: 5.037

Review 5.  Dilated cardiomyopathy: a disease of the intercalated disc?

Authors:  Jean-Claude Perriard; Alain Hirschy; Elisabeth Ehler
Journal:  Trends Cardiovasc Med       Date:  2003-01       Impact factor: 6.677

6.  Myotilin, the limb-girdle muscular dystrophy 1A (LGMD1A) protein, cross-links actin filaments and controls sarcomere assembly.

Authors:  Paula Salmikangas; Peter F M van der Ven; Maciej Lalowski; Anu Taivainen; Fang Zhao; Heli Suila; Rolf Schröder; Pekka Lappalainen; Dieter O Fürst; Olli Carpén
Journal:  Hum Mol Genet       Date:  2003-01-15       Impact factor: 6.150

7.  The changes of the cardiac structure and function in cTnTR141W transgenic mice.

Authors:  Feng Juan; Dong Wei; Quan Xiongzhi; Di Ran; Ma Chunmei; Huang Lan; Qin Chuan; Zhang Lianfeng
Journal:  Int J Cardiol       Date:  2008-08-01       Impact factor: 4.164

8.  Tetramethylpyrazine scavenges superoxide anion and decreases nitric oxide production in human polymorphonuclear leukocytes.

Authors:  Zhaohui Zhang; Taotao Wei; Jingwu Hou; Gengshan Li; Shaozu Yu; Wenjuan Xin
Journal:  Life Sci       Date:  2003-04-18       Impact factor: 5.037

9.  Remodeling the intercalated disc leads to cardiomyopathy in mice misexpressing cadherins in the heart.

Authors:  M Celeste Ferreira-Cornwell; Yang Luo; Navneet Narula; Jennifer M Lenox; Melanie Lieberman; Glenn L Radice
Journal:  J Cell Sci       Date:  2002-04-15       Impact factor: 5.285

10.  Alterations at the intercalated disk associated with the absence of muscle LIM protein.

Authors:  E Ehler; R Horowits; C Zuppinger; R L Price; E Perriard; M Leu; P Caroni; M Sussman; H M Eppenberger; J C Perriard
Journal:  J Cell Biol       Date:  2001-05-14       Impact factor: 10.539

View more
  5 in total

1.  Identification of target genes in cardiomyopathy with fibrosis and cardiac remodeling.

Authors:  Jianquan Zhao; Tiewei Lv; Junjun Quan; Weian Zhao; Jing Song; Zhuolin Li; Han Lei; Wei Huang; Longke Ran
Journal:  J Biomed Sci       Date:  2018-08-16       Impact factor: 8.410

2.  Postnatal Growth Restriction in Mice Alters Cardiac Protein Composition and Leads to Functional Impairment in Adulthood.

Authors:  Joseph R Visker; Lawrence J Dangott; Eric C Leszczynski; David P Ferguson
Journal:  Int J Mol Sci       Date:  2020-12-12       Impact factor: 5.923

3.  Prioritizing disease candidate proteins in cardiomyopathy-specific protein-protein interaction networks based on "guilt by association" analysis.

Authors:  Wan Li; Lina Chen; Weiming He; Weiguo Li; Xiaoli Qu; Binhua Liang; Qianping Gao; Chenchen Feng; Xu Jia; Yana Lv; Siya Zhang; Xia Li
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

Review 4.  Mechanisms and Clinical Application of Tetramethylpyrazine (an Interesting Natural Compound Isolated from Ligusticum Wallichii): Current Status and Perspective.

Authors:  Yingke Zhao; Yue Liu; Keji Chen
Journal:  Oxid Med Cell Longev       Date:  2016-09-07       Impact factor: 6.543

5.  Synthesis, biological evaluation, and pharmacokinetic study of novel liguzinediol prodrugs.

Authors:  Zheng Liu; Wei Li; Hong-Mei Wen; Hui-Min Bian; Jing Zhang; Lei Chen; Long Chen; Kun-Di Yang
Journal:  Molecules       Date:  2013-04-18       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.